KRAS mutation in lung metastases from colorectal cancer: Prognostic implications

Cancer Medicine

Volumn 5, Issue 2, 2016, Pages 256-264

  Ghidini, Michele ^a   Personeni, Nicola ^a,b   Bozzarelli, Silvia ^a   Baretti, Marina ^a   Basso, Gianluca ^a   Bianchi, Paolo ^a   Tronconi, Maria Chiara ^a   Pressiani, Tiziana ^a   Grizzi, Fabio ^a   Giordano, Laura ^a   Malesci, Alberto ^a,b   Alloisio, Marco ^a   Laghi, Luigi ^a   Santoro, Armando ^a,c   Rimassa, Lorenza ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c HUMANITAS UNIVERSITY   (Italy)

Author keywords

KRAS; BRAF; Brain metastases; Cancer; Colorectal; Lung metastases

Indexed keywords

B RAF KINASE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; RAS PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BRAF GENE; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; COLON CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXON; FEMALE; GENE FUNCTION; GENE MUTATION; HUMAN; HUMAN TISSUE; KRAS GENE; LOSS OF FUNCTION MUTATION; LUNG METASTASIS; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; METASTASIS RESECTION; ONCOGENE; OVERALL SURVIVAL; PIK3CA GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PTEN GENE; RETROSPECTIVE STUDY; STEREOTACTIC RADIOSURGERY; COLORECTAL NEOPLASMS; FOLLOW UP; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84983146321     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.592     Document Type: Article

References (36)

1. Misiakos, E. P., N. P. Karidis, and G. Kouraklis 2011. Current treatment for colorectal liver metastases. World J. Gastroenterol. 17:4067-4075.
2. Penna, C., and B. Nordlinger 2002. Colorectal metastasis (liver and lung). Surg. Clin. North Am. 82:1075-1090; x-xi.
3. Mitry, E., B. Guiu, S. Cosconea, V. Jooste, J. Faivre, and A. M. Bouvier 2010. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut 59:1383-1388.
4. Suzuki, H., M. Kiyoshima, M. Kitahara, Y. Asato, and R. Amemiya 2015. Long-term outcomes after surgical resection of pulmonary metastases from colorectal cancer. Ann. Thorac. Surg. 99:435-440.
5. Gonzalez, M., and P. Gervaz 2015. Risk factors for survival after lung metastasectomy in colorectal cancer patients: systematic review and meta-analysis. Future Oncol. 11:31-33.
6. Kim, H. K., J. H. Cho, H. Y. Lee, J. Lee, and J. Kim 2014. Pulmonary metastasectomy for colorectal cancer: how many nodules, how many times? World J. Gastroenterol. 20:6133-6145.
7. Sclafani, F., M. Incarbone, L. Rimassa, N. Personeni, L. Giordano, M. Alloisio, and A. Santoro 2013. The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer. J. Thorac. Cardiovasc. Surg. 145:97-103.
8. Schweiger, T., B. Hegedus, C. Nikolowsky, Z. Hegedus, I. Szirtes, R. Mair, P. Birner, et al. 2014. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study. Ann. Surg. Oncol. 21:946-954.
9. Tie, J., L. Lipton, J. Desai, P. Gibbs, R. N. Jorissen, M. Christie, K. J. Drummond, et al. 2011. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin. Cancer Res. 17:1122-1130.
10. Kim, M. J., H. S. Lee, J. H. Kim, Y. J. Kim, J. H. Kwon, J. O. Lee, S. M. Bang, et al. 2012. Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer 12:347.
11. Yaeger, R., E. Cowell, J. F. Chou, A. N. Gewirtz, L. Borsu, E. Vakiani, D. B. Solit, et al. 2015. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer 121:1195-1203.
12. Renaud, S., B. Romain, P. E. Falcoz, A. Olland, N. Santelmo, C. Brigand, S. Rohr, et al. 2015. KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer. Br. J. Cancer 112:720-728.
13. Morris, V. K., F. A. Lucas, M. J. Overman, C. Eng, M. P. Morelli, Z. Q. Jiang, R. Luthra, et al. 2014. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann. Oncol. 25:2008-2014.
14. Cejas, P., M. Lopez-Gomez, C. Aguayo, R. Madero, Carpeno J. de Castro, C. Belda-Iniesta, J. Barriuso, et al. 2009. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS ONE 4:e8199.
15. Pereira, A. A., J. F. Rego, V. Morris, M. J. Overman, C. Eng, C. R. Garrett, A. T. Boutin, et al. 2015. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br. J. Cancer 112:424-428.
16. Van Cutsem, E., C. H. Kohne, I. Lang, G. Folprecht, M. P. Nowacki, S. Cascinu, I. Shchepotin, et al. 2011. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29:2011-2019.
17. Richman, S. D., M. T. Seymour, P. Chambers, F. Elliott, C. L. Daly, A. M. Meade, G. Taylor, et al. 2009. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J. Clin. Oncol. 27:5931-5937.
18. Andreyev, H. J., A. R. Norman, D. Cunningham, J. Oates, B. R. Dix, B. J. Iacopetta, J. Young, et al. 2001. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br. J. Cancer 85:692-696.
19. Hutchins, G., K. Southward, K. Handley, L. Magill, C. Beaumont, J. Stahlschmidt, S. Richman, et al. 2011. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J. Clin. Oncol. 29:1261-1270.
20. Kemeny, N. E., J. F. Chou, M. Capanu, A. N. Gewirtz, A. Cercek, T. P. Kingham, W. R. Jarnagin, et al. 2014. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer 120:3965-3971.
21. Vauthey, J. N., G. Zimmitti, S. E. Kopetz, J. Shindoh, S. S. Chen, A. Andreou, and S. A. Curley, et al. 2013. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann. Surg. 258:619-626; discussion 626-617.
22. Umeda, Y., T. Nagasaka, Y. Mori, H. Sadamori, D. S. Sun, S. Shinoura, R. Yoshida, et al. 2013. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. J. Hepatobiliary Pancreat. Sci. 20:223-233.
23. Mekenkamp, L. J., M. Koopman, S. Teerenstra, J. H. van Krieken, L. Mol, I. D. Nagtegaal, and C. J. Punt 2010. Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br. J. Cancer 103:159-164.
24. Moertel, C. G., T. R. Fleming, J. S. Macdonald, D. G. Haller, J. A. Laurie, and C. Tangen 1993. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 270:943-947.
25. Atreya, C. E., Z. Sangale, N. Xu, M. R. Matli, E. Tikishvili, W. Welbourn, S. Stone, et al. 2013. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer Med. 2:496-506.
26. Laghi, L., S. Beghelli, A. Spinelli, P. Bianchi, G. Basso, G. Di Caro, A. Brecht, et al. 2012. Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma. PLoS ONE 7:e46002.
27. Farina Sarasqueta, A., E. C. Zeestraten, T. van Wezel, G. van Lijnschoten, R. van Eijk, J. W. Dekker, P. J. Kuppen, et al. 2011. PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. Cell Oncol. (Dordr) 34:523-531.
28. Karapetis, C. S., S. Khambata-Ford, D. J. Jonker, C. J. O'Callaghan, D. Tu, N. C. Tebbutt, R. J. Simes, et al. 2008. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359:1757-1765.
29. Personeni, N., L. Rimassa, C. Verusio, S. Barni, L. Rubino, S. Bozzarelli, and E. Villa, et al. 2015. FOLFIRI and cetuximab every second week for first-line treatment of KRAS wild-type metastatic colorectal cancer according to phosphatase and Tensin homolog expression: a phase II study. Clin. Colorectal Cancer 14:162-169.
30. Razis, E., E. Briasoulis, E. Vrettou, D. V. Skarlos, D. Papamichael, I. Kostopoulos, E. Samantas, et al. 2008. Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. BMC Cancer 8:234.
31. Sartore-Bianchi, A., M. Martini, F. Molinari, S. Veronese, M. Nichelatti, S. Artale, F. Di Nicolantonio, et al. 2009. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 69:1851-1857.
32. Molinari, F., and M. Frattini 2013. Functions and regulation of the PTEN gene in colorectal cancer. Front Oncol. 3:326.
33. Custodio, A., and J. Feliu 2013. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Crit. Rev. Oncol. Hematol. 85:45-81.
34. Miranda, E., P. Bianchi, A. Destro, E. Morenghi, A. Malesci, A. Santoro, L. Laghi, et al. 2013. Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases. Cancer 119:266-276.
35. Douillard, J. Y., A. Rong, and R. Sidhu 2013. RAS mutations in colorectal cancer. N. Engl. J. Med. 369:2159-2160.
36. ®, version 2. Available at http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf (accessed 3 October 2014).